Covered recipient · General Payments record
ROXANNE P LATIMER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2024
$1,341.11
- Reported across 72 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $321.49 | 17 |
| Education | $32.27 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $163.24 | 7 |
| ABBVIE INC. | $86.88 | 5 |
| Acerta Pharma LLC | $46.46 | 3 |
| Lilly USA, LLC | $41.00 | 2 |
| Amgen Inc. | $16.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.62 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104140458 | CMS |
| ABBVIE INC. | $19.85 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104140460 | CMS |
| ABBVIE INC. | $19.07 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104140462 | CMS |
| ABBVIE INC. | $13.64 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104140464 | CMS |
| ABBVIE INC. | $17.70 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104140466 | CMS |
| Amgen Inc. | $16.18 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117607110 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.51 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104287794 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.08 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104234371 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.87 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104503776 | CMS |
| Lilly USA, LLC | $15.15 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135366422 | CMS |
| Lilly USA, LLC | $25.85 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135405476 | CMS |
| Novo Nordisk Inc | $16.31 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096846853 | CMS |
| Novo Nordisk Inc | $24.01 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096687484 | CMS |
| Novo Nordisk Inc | $32.27 | 06/04/2024 | Education | Undisputed | 01/23/2026 | 1096977912 | CMS |
| Novo Nordisk Inc | $24.10 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097237969 | CMS |
| Novo Nordisk Inc | $30.95 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096683301 | CMS |
| Novo Nordisk Inc | $17.64 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097050906 | CMS |
| Novo Nordisk Inc | $17.96 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097589777 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.